Last reviewed · How we verify
Altace
At a glance
| Generic name | Altace |
|---|---|
| Sponsor | Dr. Reddy's Laboratories Limited |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure (NA)
- Testing Ramipril to Prevent Memory Loss in People With Glioblastoma (PHASE2)
- Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk (NA)
- The COVID-RASi Trial (COVID-19) (PHASE3)
- Pentoxifylline on Inflammatory Markers in Non-Diabetic Chronic Kidney Disease Patients (NA)
- Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants (PHASE4)
- Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure (PHASE4)
- Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Altace CI brief — competitive landscape report
- Altace updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI